cAMPfield Therapeutics

cAMPfield Therapeutics is a private clinical-stage biopharmaceutical company developing oral medicines for immune-mediated inflammatory diseases. The company launched publicly in June 2026 with a $180 million Series A financing to advance prifemilast, a once-daily oral PDE4 inhibitor for inflammatory bowel disease. cAMPfield's lead program is being positioned as a potentially best-in-class oral therapy for ulcerative colitis and Crohn's disease, with global Phase 2 trials being initiated. The asset was in-licensed from Newsoara for rights outside Greater China, and the company was founded by Mountainfield Venture Partners together with executives involved in Humira, Entyvio, Otezla, and Zeposia. cAMPfield appears focused on building a targeted inflammatory disease company around selective PDE4 biology rather than operating as a broad discovery platform company.